ChemT Biotechnology Raises $4 Million in Seed Funding
ChemT Biotechnology, a Singapore-based company specializing in AI-driven biomanufacturing solutions, has successfully raised $4 million in a seed funding round. The round was led by Wavemaker Ventures, with participation from SEEDS, SG Growth Capital, Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.
About ChemT Biotechnology
Founded by Jie Sun, who serves as CEO, and Ling Wu, the President and Co-Founder, ChemT Biotechnology is focused on integrating artificial intelligence into the biomanufacturing process. The company's innovative approach aims to simplify the manufacturing, scaling, and delivery of advanced medicines by embedding intelligence directly into the manufacturing workflow. This strategy addresses common industry challenges such as long development timelines, unpredictable yields, and high costs.
AI-Driven Innovations
At the core of ChemT's technology is CelMo, an AI-driven Virtual Cell platform. CelMo leverages proprietary biological sequencing data to simulate cell responses to various manufacturing conditions. It aids in tracking biological processes like growth, metabolism, and stress response, enhancing manufacturing performance. According to the company, CelMo has demonstrated a 50% increase in antibody output and a 40% reduction in production timelines for CHO cells, which are widely used in producing antibodies and therapeutic proteins.
ChemT's flagship product, Chemplify, applies a similar AI-driven approach to T-cell manufacturing, crucial for advanced cancer therapies. Chemplify has shown a 50% faster development rate, threefold scalability, 60% cost reduction, and tenfold higher cell expansion yield.
Strategic Use of Funds
The newly acquired funds will be directed toward several key areas. ChemT plans to expand its AI and experimental infrastructure, advance its AI-designed molecular products toward GMP standards and regulatory readiness, and scale commercial partnerships. Additionally, the company aims to extend its platform beyond CHO and T cells to include other cellular systems like stem cells, natural killer cells, and HEK cells.
Industry and Market Impact
ChemT Biotechnology has already established commercial partnerships with over 40 pharmaceutical, biotech, and CDMO companies, positioning itself as a significant player in the biomanufacturing sector. The infusion of capital from this seed round will enable the company to further its mission of making advanced medicines more accessible and efficient to produce.
With its innovative AI technologies and strategic use of recent funding, ChemT Biotechnology is set to push the boundaries of biomanufacturing, potentially transforming how advanced therapies are developed and delivered globally.